MGC Pharmaceuticals distribution partner, AMC Holdings, has placed an initial order for 1000 units of CimetrA to fast track the approval process for the medication to be distributed and sold in the US.
European based bio-pharma company specialising in the production and development of phytomedicines, MGC Pharma, has signed a Supply and Distribution Agreement with AMC Holdings. AMC has now formally submitted the initial order on an expedited basis.
The units will be shipped to a Tampa area pharmacy where they will be analysed in order to make comparisons with MGC Pharma’s research lab in Slovenia, and will be held for research and regulatory purposes.
MGC Pharma CEO and Managing Director, Roby Zomer, commented: “AMC are already making significant progress in propelling CimetrA, CannEpil and CogniCann to Clinical Trial stage in the US and we are pleased that they have cemented relationships with these prestigious institutions for the continued research into our products.”
“As the US endures a COVID spike, keeping COVID positive patients out of the hospital has become a major policy objective of countless state Governors and their health departments. For every 1000 patients who are treated effectively and kept out of hospital, the state or healthcare systems save US$40M, a rare instance where clinical and financial imperatives are perfectly harmonised,” added Brent Yessin, general counsel for AMC.
AMC is currently working with both the University of South Florida (USF) in Tampa, and the Holy Cross Hospital in Fort Lauderdale, to submit CimetrA, and shortly after CogniCann, to their respective Internal Review Boards for approval.
The approval from these boards is the first step for both facilities to join the Clinical Trials which are underway in Israel, and to launch US based clinical trials. Further to the proposed research development at USF and Holy Cross Hospital, AMC is working to establish a number of US based Clinical Trials for MGC Pharma’s products, including CimetrA CannEpil and CogniCann in Florida, Texas.
[activecampaign form=31]
